Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors.

Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors.

Item
http://www.wikidata.org/entity/Q37454285
Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trialsReviewing 15 years of experience with sirolimusFirst-in-human study of the safety and efficacy of TOL101 induction to prevent kidney transplant rejectionSystemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant.Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo.Brucella Dysregulates Monocytes and Inhibits Macrophage Polarization through LC3-Dependent Autophagy.Sirolimus conversion efficacy for graft function improvement and histopathology in renal recipients with mild to moderate renal insufficiency.Immunosuppression in kidney transplantation.Intranasal rapamycin rescues mice from staphylococcal enterotoxin B-induced shock.Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.Clinical application of mTORi based immunosuppression for renal transplantation in India.Therapeutic down-modulators of staphylococcal superantigen-induced inflammation and toxic shock.Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term OutcomesRapamycin unbalances the polarization of human macrophages to M1.Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies.Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database.Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year.
P2860

Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors.

Item
http://www.wikidata.org/entity/Q37454285
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sirolimus in kidney transplant ...... ithout calcineurin inhibitors.
@en
Sirolimus in kidney transplant ...... ithout calcineurin inhibitors.
@nl
type
label
Sirolimus in kidney transplant ...... ithout calcineurin inhibitors.
@en
Sirolimus in kidney transplant ...... ithout calcineurin inhibitors.
@nl
prefLabel
Sirolimus in kidney transplant ...... ithout calcineurin inhibitors.
@en
Sirolimus in kidney transplant ...... ithout calcineurin inhibitors.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Sirolimus in kidney transplant ...... ithout calcineurin inhibitors.
@en
P2093
P304
P31
P356
10.1097/TP.0B013E3181A059A1
P433
P478
P577
P698